BAIYUNSHAN PH_Providing professional financial news and data related to BAIYUNSHAN PH, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

BAIYUNSHAN PH (00874.HK): Guangzhou Pharmaceutical Disposes Accounts Receivable of Approximately RMB 149 Million

Tags：

BAIYUNSHAN PH 00874.HK Disposal of Receivables

2026-08-28

BAIYUNSHAN PH (00874.HK): Subsidiary's Norepinephrine Bitartrate Injection Passes Generic Drug Consistency Evaluation

Tags：

BAIYUNSHAN PH 00874.HK R&D Progress

2026-08-24

BAIYUNSHAN PH (00874.HK): subsidiary's Citicoline Sodium Injection obtains supplementary drug application approval and consistency evaluation

Tags：

BAIYUNSHAN PH 00874.HK Pharmaceutical

2026-08-19

BAIYUNSHAN PH (00874.HK): subsidiary's Cefazolin Sodium for Injection obtains Macao pharmaceutical registration certificate, to be sold in Macao under authorization

Tags：

BAIYUNSHAN PH 00874.HK Drug Registration Certificate

2026-08-17

BAIYUNSHAN PH(00874.HK): Subsidiary Zhongyi Pharmaceutical Obtains Revised Drug Production Licence with Removal of Production Site and Change of Production Person‑in‑Charge

Tags：

BAIYUNSHAN PH 00874.HK Drug Production Licence

2026-08-04

BAIYUNSHAN PH (00874.HK): Cefalexin Capsules Obtain Proprietary Medicine Registration Certificate from Macao Drug Administration

Tags：

BAIYUNSHAN PH 00874.HK drug registration application

2026-07-20

BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation

Tags：

BAIYUNSHAN PH 00874.HK NMPA Approval

2026-07-09

BAIYUNSHAN PH(00874.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 1.78 billion, YoY decrease of 2.06%

Tags：

BAIYUNSHAN PH 00874.HK financials

2026-04-27

Scan QR Code

Download App